Clinical Trials

EBC-46 Clinical Trials 2025–2026: Soft Tissue Sarcoma, Melanoma, and the Path to Approval

A detailed review of EBC-46 (tigilanol tiglate) human clinical trial data through 2025–2026, including Phase I/II results for soft tissue sarcoma, melanoma, and other solid tumours, response rates, and the path to FDA approval.

By Marcus Webb

See all

EBC46 Research Hub

Independent research and analysis on EBC-46 (tigilanol tiglate) and Blushwood berry extract. Covering peer-reviewed science, clinical trials, and the latest developments in this emerging field.

Sign up

Powered by Ghost

Follow the Research

Get updates on EBC-46 clinical trials, Blushwood berry science, and supplement findings — delivered to your inbox.